<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05082545</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-2002-102</org_study_id>
    <secondary_id>SHR-2002-I-102</secondary_id>
    <nct_id>NCT05082545</nct_id>
  </id_info>
  <brief_title>Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors</brief_title>
  <official_title>A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SHR-2002 Injection in Combination With SHR-1316 in Patients With Advanced Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atridia Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atridia Pty Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is Phase 1 study FIH to check &quot;Dose Escalation, Dose expansion and Indication&#xD;
      expansion&quot;. This study is AUSTRALIA only study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Screening up to study completion, an average of 2 years</time_frame>
    <description>Number of subjects with adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v.5.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK of SHR-2002 + SHR-1316</measure>
    <time_frame>Before and after SHR-2002 and SHR-1316 infusion throughout the study, an average of 2 years</time_frame>
    <description>To check Maximum concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of SHR-2002 + SHR-1316</measure>
    <time_frame>Before and after SHR-2002 and SHR-1316 infusion throughout the study, an average of 2 years</time_frame>
    <description>To check AUC last</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of SHR-2002 + SHR-1316</measure>
    <time_frame>Before and after SHR-2002 and SHR-1316 infusion throughout the study, an average of 2 years</time_frame>
    <description>ADA of SHR-2002 + SHR-1316</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Advanced Malignant Tumors</condition>
  <arm_group>
    <arm_group_label>Dose escalation:SHR-2002+SHR-1316</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-2002 +SHR-1316 C1D1 SHR-2002,C1D22 SHR-2002+SHR-1316, C2 SHR-2002+SHR-1316</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion stage: SHR-2002+SHR-1316</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion of SHR-2002 will be decided after finishing few cohorts in Dose escalation part.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indication expansion stage：SHR-2002+SHR-1316</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indication expansion of SHR-2002 will be decided after finishing few cohorts in Dose expansion part.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-2002 and SHR-1316</intervention_name>
    <description>Cohort study</description>
    <arm_group_label>Dose escalation:SHR-2002+SHR-1316</arm_group_label>
    <arm_group_label>Dose expansion stage: SHR-2002+SHR-1316</arm_group_label>
    <arm_group_label>Indication expansion stage：SHR-2002+SHR-1316</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subjects must meet all the following criteria to be eligible for enrollment into the study:&#xD;
&#xD;
          1. Ability to understand and voluntarily agrees to participate by giving written informed&#xD;
             consent for the study;&#xD;
&#xD;
          2. Male or female aged ≥18 years at the time of signing the ICF;&#xD;
&#xD;
          3. Histopathologically or cytologically documented advanced or metastatic malignancies&#xD;
             and failed or intolerable to previous standard therapy, has no available standard of&#xD;
             care therapy or refused standard therapy;&#xD;
&#xD;
          4. An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1&#xD;
             (Appendix 2);&#xD;
&#xD;
          5. Female and male patients of reproductive potential must agree to use highly effective&#xD;
             contraception during the study treatment period and within 6 months after the last&#xD;
             investigational drug administration.&#xD;
&#xD;
        Subjects who meet any of the following criteria will be excluded from the study:&#xD;
&#xD;
          1. Patients with known active central nervous system (CNS) metastases and/or&#xD;
             carcinomatous meningitis.&#xD;
&#xD;
          2. Patients with tumor-related pain that cannot be controlled as determined by the&#xD;
             investigator.&#xD;
&#xD;
          3. Systemic anti-tumor therapy within 28 days prior to the first dose of the study&#xD;
             treatment&#xD;
&#xD;
          4. History of autoimmune diseases, except for Type 1 diabetes (blood glucose can be&#xD;
             controlled by insulin therapy)&#xD;
&#xD;
          5. History of clinically significant cardiovascular or cerebrovascular diseases within 6&#xD;
             months prior to the first dose of study treatment.&#xD;
&#xD;
          6. Known history of serious allergic reactions to the investigational product or its main&#xD;
             ingredients;&#xD;
&#xD;
          7. History of immunodeficiency, including positive HIV serum test result and other&#xD;
             acquired or congenital immunodeficiency diseases, or history of organ transplantation;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kathy You, PhD</last_name>
    <phone>+61 02 9299 0433</phone>
    <email>kathyyou@atridia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ravi patel, M.Pharm</last_name>
    <phone>0452363506</phone>
    <email>ravi.patel@atridia.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icon Cancer Centre</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Jim Coward</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linear clinical research</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Millward</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scientia Clinical research</name>
      <address>
        <city>Sydney</city>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Prachi Bhave</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sydney South West Private Hospital (SSWP)</name>
      <address>
        <city>Sydney</city>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Aflah Roohullah</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

